Title: Kybella vs Aqualyx: One Has a US Label, One Has None
Author: Arthur Harmash
Published: 2026-10-04
Source: https://lymyvoyage.com/articles/kybella-vs-aqualyx-one-has-a-us-label-one-has-none
Citations:
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553
- https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=aqualyx
- https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=kabelline
- https://www.gov.uk/government/news/crackdown-on-unsafe-cosmetic-procedures-to-protect-the-public
- https://pubmed.ncbi.nlm.nih.gov/26319076/
- https://pubmed.ncbi.nlm.nih.gov/30027646/
- https://pubmed.ncbi.nlm.nih.gov/27430612/
- https://pubmed.ncbi.nlm.nih.gov/26673433/
- https://pubmed.ncbi.nlm.nih.gov/33500794/
- https://pubmed.ncbi.nlm.nih.gov/26507958/
- https://pubmed.ncbi.nlm.nih.gov/35832164/
- https://blushlocal.net/kybella-cost/
- https://doctornyla.com/blog/aqualyx-cost-uk/
- https://www.wolverhampton.gov.uk/food-businesses-and-safety/non-surgical-aesthetic-procedures-what-you-need-know
- https://turkeyluxuryclinics.com/en/blog/how-much-are-fat-dissolving-injections
---
Two injections sold for the same purpose share an active ingredient. Deoxycholic acid dissolves fat cell membranes, and it is what does the work in both Kybella and Aqualyx.
That is where the sameness ends. One of them is a medicine approved for a single area of the body, with two phase 3 trials behind it and a nerve-injury warning on its label. The other has no American approval at all, and a published literature of five papers.
Kybella and Aqualyx both inject deoxycholic acid to break down fat. One costs about 600 dollars a vial, the other about 250 pounds a session. Same drug, different price?
Not the same object. A price comparison assumes two products are alternatives. Regulators have not treated these two as alternatives, and the wholesalers selling both to injectors are the ones publishing most of the comparisons.
Kybella's American label approves it for submental fat, the pad under the chin, and states it is not approved for use anywhere else on the body. Two placebo-controlled trials randomised more than a thousand people between them.
Search the medical literature for Aqualyx and five records come back. One is a 186-patient retrospective series. Two are case reports: skin necrosis, and chronic infection with nodules after injection by untrained personnel.
The American label database has no entry for Aqualyx, and none for Kabelline either. That is not a safety verdict. It means there is no approved indication, no approved dose and no required warning to compare against.
What complicates the case: Kybella's own trials are not a clean result. Marginal mandibular nerve paresis, a temporary weakness of the smile, appeared in 4.3 percent of treated patients in one trial, and two thirds of patients got only a one-grade improvement.
What the evidence cannot show is whether Aqualyx is more dangerous. Nobody has run the trial. Absence of published harm at scale and evidence of safety are different things, and the five papers cannot tell them apart.
So the question to ask is not which is cheaper per session. It is which body area the product you are being offered has ever been approved or tested for, and what the label says when something goes wrong.
## What each product is actually licensed to do
| | Kybella | Aqualyx |
|---|---|---|
| Active ingredient | Deoxycholic acid[^1] | Deoxycholic acid, in a galactose solution[^5] |
| US approval | Yes, current label revised September 2026[^1] | No entry in the US label database[^2] |
| Approved body area | Submental fat only; "not approved for use outside the submental region"[^1] | None in the US; described in the literature as a European CE-marked product[^5][^6] |
| Dose rules | 2 mg per injection, up to 100 mg and 50 injections per treatment, maximum 6 treatments[^1] | No US label, so no approved maximum[^2] |
| Randomised trials | Two phase 3 placebo-controlled trials, 1,022 patients[^7][^8] | None in the five records the medical literature holds[^5][^6][^9][^10][^11] |
| Labelled warnings | Marginal mandibular nerve injury; dysphagia in 2 percent[^1] | No US label, so no required warning[^2] |
The CE mark named in that table is a European conformity marking, and it is not an American approval or its equivalent. It certifies that a product meets European requirements for its category, which is a different test from the one a medicine passes to reach a US label.
The right column is a description of a regulatory gap, not a finding about danger. The distinction is the whole point of this comparison, and the article returns to it below.
## Kybella: one area, six treatments, and a warning about the smile
Kybella's American prescribing information is specific about where it may go. The approved indication is "improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults", and the label states that it is not approved for use outside the submental region.[^1] Submental means under the chin.
The dosing is equally bounded. Each injection is 2 mg in 0.2 mL. A single treatment may use up to 100 mg across a maximum of 50 injections, and a patient may have no more than six treatments, at least a month apart.[^1] The label was revised in September 2026, so this is current, not historical.
Two warnings carry over from the trials. Marginal mandibular nerve injury, which shows up as an asymmetric smile or facial muscle weakness, occurred in clinical trials; all reported cases resolved without treatment, over a range of 1 to 298 days and a median of 44.[^1] Difficulty swallowing occurred in 2 percent of treated patients, resolving in a median of 3 days.[^1]
The evidence behind that approval is two trials of nearly identical design. REFINE-1 randomised 506 adults and reported that 70.0 percent of treated patients achieved at least a one-grade composite improvement against 18.6 percent on placebo, with at least a two-grade improvement in 13.4 percent against none on placebo.[^8] REFINE-2 randomised 516 and reported 66.5 percent against 22.2 percent, and 18.6 percent against 3.0 percent.[^7]
Read those numbers as a patient rather than as a regulator. The common outcome is a one-grade improvement on a five-point scale, not the disappearance of a double chin, and roughly a third of treated patients did not reach even that. REFINE-1 also reported marginal mandibular nerve paresis in 4.3 percent of treated subjects, mostly mild and transient.[^8]
## Aqualyx: five papers, two of them case reports
A search of PubMed, the National Library of Medicine's index of biomedical literature, returns five records for Aqualyx.[^5] That is the entire indexed literature, and it is worth listing.
The largest is a four-year retrospective review of 186 patients, which reported mild swelling and redness resolving within days and stated that "no major complications or side effects occurred, such as necrosis".[^5] A prospective study of ultrasound-guided injection to the inside of the knees found reduced circumference in 71.42 percent of its patients, and had seven of them.[^9] A third paper treated 17 lipomas and achieved complete removal in 70.59 percent.[^6]
The remaining two are case reports of harm. One describes skin necrosis after injection of an adipocytolytic solution.[^10] The other describes chronic infection, painful nodules and purulent lesions after deoxycholate injection administered by untrained personnel.[^11]
Kybella's two phase 3 trials randomised 1,022 patients between them, while the entire indexed literature on Aqualyx is five records, two of which are case reports of necrosis or chronic infection.[^5][^7][^8]
The same literature cannot agree on what kind of product Aqualyx is. A 2015 paper in Aesthetic Surgery Journal calls it "A CE-Marked Drug Used for Localized Adiposity Reduction".[^5] A 2019 paper by an overlapping author group calls it "a Class III CE-marked device".[^6] Drug and device are different regulatory categories with different evidence requirements, and the difference is not cosmetic.
## What the American label database says, and what it does not
Querying the label service run by the National Library of Medicine returns one record for Kybella and none for Aqualyx.[^1][^2] A query for Kabelline, one of the Korean-made products sold on the same promise, also returns nothing.[^3]
That absence has a precise meaning and no more. It means no approved indication exists, so no body area has been authorised. No approved dose exists, so no maximum applies. And no labelled warning exists, so nothing has to be disclosed to a patient in the way Kybella's nerve-injury paragraph does.
It does not mean the product is more dangerous than the approved one. Nobody has run the trial that would establish that either way. This is where most comparisons of these two products go wrong, and they go wrong in both directions. One error treats a European marketing authorisation as equivalent to an American approval. The other treats an absence of American approval as evidence of harm.
## The price gap is partly a gap in what was tested
Prices are where patients start, so it is worth putting them next to the evidence.
One price aggregation across 21 American clinic price lists gives a median of 600 dollars per Kybella vial, with the middle of the range between 500 and 736 dollars.[^12] Most patients need two to four vials a session and two to six sessions.
A London and Cheshire clinic group's 2026 guide prices Aqualyx at about 150 to 400 pounds a session for a small area such as a double chin.[^13] Abdomen, flanks or thighs run 250 to 650 pounds or more, and a small-area course 400 to 1,100 pounds. Many patients need two to four sessions.
So a course of the approved product runs into thousands of dollars and a course of the unapproved one into hundreds of pounds. Part of that difference is the cost of two phase 3 trials, a submission and a label. Part of it is that the cheaper product is being offered for body areas no regulator has authorised any deoxycholic acid injection to treat.
Notably, the Aqualyx price guide says nothing at all about regulatory status, licensing or who may lawfully inject it.[^13] Neither does it have to.
## Abroad, the ladder is visible on one page
A Turkish clinic aggregator's 2026 guide prices all of these products in one table, which makes the structure of the market unusually easy to see.[^15]
| Product, as the page lists it | Price per session in Turkey | Indexed literature |
|---|---|---|
| Kybella | 500 to 1,500 dollars[^15] | Two phase 3 trials, 1,022 patients[^7][^8] |
| Aqualyx | 200 to 500 dollars[^15] | Five records, two of them case reports[^5] |
| Lipo Lab or Kabelline | 75 to 250 dollars[^15] | No US label; no indexed literature found[^3] |
The same page puts a session in the United States at 600 to 1,800 dollars, the United Kingdom at 300 to 600, and Turkey at 200 to 500.[^15]
It also names Kybella as approved by the US Food and Drug Administration and gives no regulatory information at all for the other three.[^15] That is the omission this article is about, stated by a seller rather than about one: the one product whose approval status is advertised is the one that has an approval to advertise.
## What the quoted price leaves out
**Who is allowed to hold the syringe.** In the United Kingdom, a treatment requiring a prescription requires a prescriber. One local authority's guidance for non-surgical aesthetic procedures states that "for treatments which require a prescription, a face-to-face consultation must be performed by a suitably qualified prescriber", naming doctors, dentists, prescribing nurses and pharmacists.[^14] A remote form is not that consultation.
**The rules are being tightened while these prices are being quoted.** In August 2025 the Department of Health and Social Care announced restrictions on the highest-risk non-surgical procedures.[^4] Only qualified healthcare professionals working for providers registered with the Care Quality Commission will be allowed to perform them, with a licensing scheme and training standards for lower-risk treatments. Fat-dissolving injections were not named in that announcement, which is worth knowing before assuming the category is covered.
**The case report names the mechanism of the worst outcome.** The chronic-infection case describes injection by untrained personnel.[^11] That is a claim about who injected, not about which brand was in the syringe, and it is the variable a price comparison never shows.
**Nobody is following these patients.** There is no registry for fat-dissolving injections in any of the markets discussed. The five papers on Aqualyx are what exists, and two of them exist because something went wrong badly enough for a surgeon to write it up.
## How to use this before booking
Ask which product, by brand name, and ask for the body area it is licensed or approved for. If the area you want treated is not that area, you are the evidence base.
Ask who will inject it and whether they can prescribe. In the United Kingdom that means a face-to-face consultation with a prescriber before anything is supplied.
Ask what the maximum dose per session is and where that maximum comes from. For Kybella the answer is on the label: 100 mg, 50 injections, six treatments. For an unapproved product there is no published answer, and the honest version of that reply is that the clinic sets it.
Compare courses, not sessions. Two to four vials across two to six sessions is the unit that matters for the approved product, and two to four sessions for the other.
And treat the absence of a label as a missing document rather than a verdict. It tells you what has not been established, which is exactly the information a price per session is not carrying.
[^1]: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553 — US National Library of Medicine, DailyMed, "KYBELLA (deoxycholic acid) injection, solution", Kythera Biopharmaceuticals Inc., distributed by AbbVie Inc., label revised September 2026. Accessed Sep 30, 2026.
[^2]: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=aqualyx — US National Library of Medicine, DailyMed label service query for "Aqualyx", returning zero records. Queried Sep 30, 2026.
[^3]: https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=kabelline — US National Library of Medicine, DailyMed label service query for "Kabelline", returning zero records. Queried Sep 30, 2026.
[^4]: https://www.gov.uk/government/news/crackdown-on-unsafe-cosmetic-procedures-to-protect-the-public — Department of Health and Social Care, "Crackdown on unsafe cosmetic procedures to protect the public" (published Aug 6, 2025). Accessed Sep 30, 2026.
[^5]: https://pubmed.ncbi.nlm.nih.gov/26319076/ — Rauso R, Salti G, "A CE-marked drug used for localized adiposity reduction: a 4-year experience", Aesthetic Surgery Journal 2015, abstract record via PubMed; the same search returns the complete five-record indexed literature for Aqualyx. Accessed Sep 30, 2026.
[^6]: https://pubmed.ncbi.nlm.nih.gov/30027646/ — Mlosek RK, Malinowska S, Woźniak W, "Lipoma removal using a high-frequency ultrasound-guided injection of a Class III CE-marked device", Journal of Cosmetic Dermatology 2019, abstract record via PubMed. Accessed Sep 30, 2026.
[^7]: https://pubmed.ncbi.nlm.nih.gov/27430612/ — Humphrey S, Sykes J, Kantor J, et al., "ATX-101 for reduction of submental fat: a phase III randomized controlled trial" (REFINE-2), Journal of the American Academy of Dermatology 2016;75(4), abstract record via PubMed. Accessed Sep 30, 2026.
[^8]: https://pubmed.ncbi.nlm.nih.gov/26673433/ — Jones DH, Carruthers J, Joseph JH, et al., "REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101", Dermatologic Surgery 2016;42(1), abstract record via PubMed. Accessed Sep 30, 2026.
[^9]: https://pubmed.ncbi.nlm.nih.gov/33500794/ — Mlosek RK, et al., "The efficacy of high-frequency ultrasound-guided injection lipolysis in reducing fat deposits located on the inside of the knees", Journal of Ultrasonography 2021, abstract record via PubMed. Accessed Sep 30, 2026.
[^10]: https://pubmed.ncbi.nlm.nih.gov/26507958/ — Di Toro G, Rauso R, "Skin necrosis following adipocitolitic solution injections", Aesthetic Surgery Journal 2016, abstract record via PubMed. Accessed Sep 30, 2026.
[^11]: https://pubmed.ncbi.nlm.nih.gov/35832164/ — Shahid S, Al-Hassani F, "Chronic infection and nodule formation following deoxycholate injection", Archives of Plastic Surgery 2022, abstract record via PubMed. Accessed Sep 30, 2026.
[^12]: https://blushlocal.net/kybella-cost/ — BlushLocal, "Kybella Cost (2026)", a price aggregation across 21 retained clinic price lists, data observed Aug 25, 2026. Accessed Sep 30, 2026.
[^13]: https://doctornyla.com/blog/aqualyx-cost-uk/ — Dr Nyla Medispa (Mayfair, Alderley Edge, Crosby), "Aqualyx Cost in the UK: 2026 Price Guide" (last modified Sep 25, 2026). Accessed Sep 30, 2026.
[^14]: https://www.wolverhampton.gov.uk/food-businesses-and-safety/non-surgical-aesthetic-procedures-what-you-need-know — City of Wolverhampton Council, "Non-surgical aesthetic procedures: what you need to know" (dated Mar 19, 2026). Accessed Sep 30, 2026.
[^15]: https://turkeyluxuryclinics.com/en/blog/how-much-are-fat-dissolving-injections — Turkey Luxury Clinics, "How Much Do Fat Dissolving Injections Cost? 2026 Prices" (last updated Jun 28, 2026). Accessed Sep 30, 2026.